Replies to post #113061 on Biotech Values

[DewDiligence]

I’m referring not to a deficiency in Prolia reimbursement, but rather to the awkwardness of patients’ having to go to a pharmacy and then make a separate trip to a doctor’s office or clinic. Even AMGN acknowledges that this process may have slowed commercial uptake.